|Day Low/High||119.35 / 120.93|
|52 Wk Low/High||82.95 / 128.54|
Let's take a peek at overnight and early-morning price action in the major asset classes. Exit light Enter night Take my hand We're off to never never land. -- Metallica, "Enter Sandman" Let's take a peek at overnight and early-morning price action ...
The objective of investing is to offset future liabilities and manage risk.
TheStreet's Jim Cramer says Abbott Labs will benefit from growth in emerging markets and Glaxo will benefit from a "huge pipeline of approvals." The Action Alerts Plus portfolio recently bought Glaxo shares and added to their position in Abbott Labs.
Plenty of leadership remains in the health care sector and there's reason to see further potential.
Trading at 7x earnings, these stocks are all poised to outperform the market this year.
Don't chase recent winners, search for stocks that have good 2013 prospects.
How much to sell? My mavens on the floor see $1.6 billion to sell market on close, so my observation earlier in the afternoon might have had some merit. In terms of sectors, the largest to buy include health care ($ 85 ,million) and financials ($3...
Being behind the market or beating estimates isn't enough; guidance has to be good.
Recent company-related activities are worth noting and could merit action.
Nicole Urken, research associate of Jim Cramer, likes Abbott Labs and says it's not just an Obama trade.
Abbott gets some good news on its Hep C drug, which has buoyed Bristol-Myers. Some positive Hep C data out of Abbott Labs (ABT) (hat tip Steph Link!) is buyoing Bristol-Myers Squibb (BMY) this morning.
Here is this week's roundup of the dumbest actions on Wall Street.
Senior columnist Adam Feuerstein says hepatitis drugs are the next big thing to watch in biotech.
In this episode of Buy This, Sell That!, Robert Zagunis, portfolio manager for the Jensen Quality Growth fund, names his favorite stocks including Abbott Labs, UPS and Praxair.